Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
Commentary|Videos|November 10, 2026
Dr Nunnery on Chemo De-Escalation, Ovarian Function Suppression, and Toxicity Management in Breast Cancer
Author(s)Sara Nunnery, MD, MSCI
Fact checked by: Ashling Wahner
Sara Nunnery, MD, MSCI, discusses genomic testing, ovarian function suppression, and toxicity management in hormone receptor–positive breast cancer.
Advertisement
“[We need] to make sure that we are identifying patients who can avoid the toxicity of chemotherapy and not have to have that treatment as part of their treatment plan.”
Advertisement
Related to this article
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026.
Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pimicotinib for Symptomatic TGCT
2
Dr Backes on BEHOLD-1 Data With Mocertatug Rezetecan in Platinum-Resistant Ovarian Cancer
3
Longer Follow-Up of BEHOLD-1 Shows Durable Responses With Mo-Rez in Platinum-Resistant Ovarian Cancer
4
Prizlon-Cel Nets FDA RMAT and Fast Track Designations in R/R LBCL
5